VTUS Related StreetInsider.com Reports
-
Unusual 11 Mid-Day Movers 01/30: (MERU) (BIOC) (MGAM) Higher; (VTUS) (KTCC) (MTOR) Lower
-
StreetInsider.com Pre-Open Movers 01/30: (CPNO) (CHK) (AMZN) Higher; (CODE) (WBSN) (MTOR) Lower (more...)
-
Ventrus Bio (VTUS) Prices $20M in Financial Actions
-
Streetinsider.com After-Hours Movers 1/29: (UIS) (AMZN) (PRXL) Higher; (VTUS) (KERX) (WBSN) Lower (more...)
-
Ventrus Bio (VTUS) Announces Common, Preferred Offering
-
Ventrus Biosciences (VTUS) Trading Near Cash Value Says Cantor Fitzgerald
-
Ventrus Biosciences (VTUS) Receives FDA Written Feedback,
-
Cantor Fitzgerald Upgrades Ventrus Biosciences (VTUS) to Buy as Oct. Catalysts Loom
-
Notable 52-Week Highs and Lows of the Day 06/25: (LXRX) (SNTA) (DG) High; (NOK) (VTUS) (KEX) (HAL) Low
-
Unusual 11 Mid-Day Movers 06/25: (JAX) (ALSK) (BIOL) Higher; (VTUS) (GEOY) (MNTA) Lower
-
Cantor Fitzgerald Cuts Rating and Price Target Ventrus Biosciences (VTUS); Phase III Trial Misses; New Exit Strategy Potential Sale
-
Morning Movers 06/25: (JAX) (LEE) (MDGN) Higher; (VTUS) (GEOY) (MNTA) (KEX) Lower
-
Pre-Open Losers 6/25: (VTUS) (MNTA) (GEOY) (more...)
-
Shares of Ventrus Biosciences (VTUS) resume trading down 25%
-
Shares of Ventrus Bioscience (VTUS) to resume trading at 7:30am ET
-
Ventrus (VTUS) Issues Results from Pivotal Phase 3 Trial of Iferanserin, Says Failed to Show Improvement from Therapy
-
Ventrus Bioscience (VTUS) trading halted with news pending
-
Brean Murray Carret & Co. Starts Ventrus Biosciences (VTUS) at Buy; Strong Clinical Data Weeks Away
-
Unusual 11 Mid-Day Movers 06/12: (AONE) (RMTR) (FSLR) Higher; (ZNGA) (FDS) (NAV) Lower
-
Ventrus Biosciences (VTUS) Files 949K Common Shelf for Shareholders
-
Unusual 11 Mid-Day Movers 05/14: (GOLF) (CSBC) (GRPN) Higher; (ACOM) (ANIK) (NQ) Lower
-
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
-
Ventrus Biosciences (VTUS) Higher On Positive Trial Results
-
Cantor Fitzgerald Starts Ventrus Biosciences (VTUS) at Buy; N-T Binary Play
-
William Blair Starts Ventrus Biosciences (VTUS) at Outperform
-
Ventrus Biosciences (VTUS) Files $100M Mixed Shelf
-
Ventrus BioSciences (VTUS) Publishes Prior Phase 2b Study on the Safety and Efficacy of Iferanserin
-
Ventrus BioSciences (VTUS) Announces Completion of Enrollment with Phase 3 Trial of Diltiazem
-
Ventrus BioSciences (VTUS) Completes Acquisition of Title to Hemorrhoids Product for $12.5 Million
-
Trading Radar for 11/14: J.C. Penney (JCP), Lowe's (LOW), Urban Outfitters (URBN), InterOil (IOC) Report
-
UPDATE: Leerink Swann Initiates Coverage on Ventrus Bioscience (VTUS) at Outperform, Strong Pipeline
-
Lazard Capital Starts Ventrus Biosciences (VTUS) at Buy
-
Leerink Swann Starts Ventrus Biosciences (VTUS) at Outperform
-
Ventrus Biosciences (VTUS) Prices Underwritten Registered Offering of 4.5 Million Shares at $10/Share
-
FDA Requests More Info from Ventrus (VTUS) for VEN 309 SPA
-
Ventrus Biosciences (VTUS) Files $47.2M Common Shelf
-
Ventrus BioSciences (VTUS) Adds Third Treatment to Iferanserin Phase III
-
Ventrus BioSciences (VTUS) Announces Improved, FDA-Recommended Endpoints Proposed for Phase III Hemorrhoid Study
-
Rodman & Renshaw Starts Ventrus Biosciences (VTUS) at Market Outperform
-
National Securities Starts Ventrus Biosciences (VTUS) at Buy
-
Ventrus Biosciences (VTUS) IPO Trades Slightly Higher
-
Ventrus Biosciences (VTUS) IPO Prices at $6
Back to VTUS Stock Lookup
